Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain

@inproceedings{Fowler2015EvidenceTF,
  title={Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain},
  author={Joanna S. Fowler and Jean Logan and Nora D. Volkow and Elena Shumay and Fred McCall-Perez and Millard Jayne and Gene-Jack Wang and David L. Alexoff and Karen Apelskog-Torres and Barbara Hubbard and Pauline Carter and Payton King and Stanley Fahn and Michelle Gilmor Gilmor and Frank Telang and Colleen Shea and Youwen Xu and Lisa Muench},
  booktitle={Neuropsychopharmacology},
  year={2015}
}
Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson’s disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline and for transdermal selegiline suggesting that when plasma levels of selegiline are elevated, brain MAO-A might also be inhibited. Zydis selegiline (Zelapar) is an orally disintegrating formulation of… CONTINUE READING